参考文献
［1］Patel P,Hanson DL,Sullivan PS,et al.Incidence of types of cancer among HIVinfected persons compared with the general population in the United States,1992-2003[J].Ann Intern Med,2008,148（10）:728-736.
［2］Coghill AE,Shiels MS,Suneja G,et al.Elevated cancer-specific mortality among HIV-infected patients in the United States[J].J Clin Oncol,2015,33（21）:2376-2383.
［3］Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71（3）:209-249.
［4］McCormack VA,Febvey Combes O,Ginsburg O,et al.Breast cancer in women living with HIV:A first global estimate[J].Int J Cancer,2018,143（11）:2732-2740.
［5］Spano JP,Lanoy E,Mounier N,et al.Breast cancer among HIV infected individuals from the ONCOVIH study,in France:therapeutic implications[J].Eur J Cancer,2012,48（18）:3335-3341.
［6］Shiels MS,Pfeiffer RM,Gail MH,et al.Cancer burden in the HIV-infected population in the United States[J].J Natl Cancer Inst,2011,103（9）:753-762.
［7］Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136（5）:E359-E386.
［8］Salmons B,Gunzburg WH.Revisiting a role for a mammary tumor retrovirus in human breast cancer[J].Int J Cancer,2013,133（7）:1530-1535.
［9］Joshi D,Buehring GC.Are viruses associated with human breast cancer?Scrutinizing the molecular evidence[J].Breast Cancer Res Treat,2012,135（1）:1-15.
［10］Vicari AP,Caux C.Chemokines in cancer[J].Cytokine Growth Factor Rev,2002,13（2）:143-154.
［11］Velasco-Velazquez M,Xolalpa W,Pestell RG.The potential to target CCL5/CCR5 in breast cancer[J].Expert Opin Ther Targets,2014,18（11）:1265-1275.
［12］Endo M,Inatsu A,Hashimoto K,et al.Human immunodeficiency virus-induced apoptosis of human breast cancer cells via CXCR4 is mediated by the viral envelope protein but does not require CD4[J].Curr HIV Res,2008,6（1）:34-42.(https://www.daowen.com)
［13］Toniolo A,Serra C,Conaldi PG,et al.Productive HIV-1 infection of normal human mammary epithelial cells[J].AIDS,1995,9（8）:859-866.
［14］Moni MA,Lio P.Network-based analysis of comorbidities risk during an infection:SARSand HIV case studies[J].BMC Bioinformatics,2014,15（1）:333.
［15］Pantanowitz L,Sen S,Crisi GM,et al.Spectrum of breast disease encountered in HIV-positive patients at a community teaching hospital[J].Breast,2011,20（4）:303-308.
［16］Gradishar WJ,Moran MS,Abraham J,et al.Breast Cancer,version 3.2022,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2022,20（6）:691-722.
［17］Grover S,Martei YM,Puri P,et al.Breast cancer and HIV in sub-Saharan Africa:A complex relationship[J].Journal of Global Oncology,2018,4（9）:1-11.
［18］Hurley J,Franco S,Gomez-Fernandez C,et al.Breast cancer and human immunodeficiency virus:a report of 20 cases[J].Clin Breast Cancer,2001,2（3）:215-221.
［19］Langenhoven L,Barnardt P,Neugut AI,et al.Phenotype and treatment of breast cancer in HIV-positive and-negative women in Cape Town,South Africa[J].J Glob Oncol,2016,2（5）:284-291.
［20］Torres HA,Rallapalli V,Saxena A,et al.Efficacy and safety of antiretrovirals in HIV-infected patients with cancer[J].Clin Microbiol Infect,2014,20（10）:O672-O679.
［21］Calvet GA,Grinsztejn BG,Quintana MS,et al.Predictors of early menopause in HIV-infected women:a prospective cohort study[J].Am J Obstet Gynecol,2015,212（6）:761-765.
［22］Gomez A,Montero AJ,Hurley J.Clinical outcomes in breast cancer patients with HIV/AIDS:a retrospective study[J].Breast Cancer Res Treat,2015,149（3）:781-788.
［23］Ryom L,De Miguel R,Cotter AG,et al.Major revision version 11.0 of the European AIDS clinical society guidelines 2021[J].HIV Med,2022,23（8）:849-858.